Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) rose 4.5% during mid-day trading on Thursday following a stronger than expected earnings report, reports. The company traded as high as $163.50 and last traded at $159.01, with a volume of 2,351,161 shares traded. The stock had previously closed at $152.23.

The company reported $1.53 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.26 by $0.27. The company had revenue of $566.60 million for the quarter, compared to the consensus estimate of $560.22 million. During the same quarter last year, the company posted $0.65 earnings per share. Alexion Pharmaceuticals’s revenue was up 67.2% compared to the same quarter last year.

Several analysts have recently commented on the stock. Analysts at Ned Davis Research upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday. Separately, analysts at Credit Suisse raised their price target on shares of Alexion Pharmaceuticals to $171.00 in a research note on Thursday, March 27th. They now have a “neutral” rating on the stock. Finally, analysts at Robert W. Baird raised their price target on shares of Alexion Pharmaceuticals from $175.00 to $199.00 in a research note on Tuesday, March 11th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Alexion Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $181.88.

The stock’s 50-day moving average is $158.5 and its 200-day moving average is $140.8. The company has a market cap of $30.706 billion and a P/E ratio of 119.87.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.